Reconstructing tumor history in breast cancer: signatures of mutational processes and response to neoadjuvant chemotherapy⋆ [0.03%]
乳腺癌中肿瘤历史的重建：突变过程和新辅助化疗反应的标志
C Denkert,M Untch,S Benz et al.
C Denkert et al.
Background: Different endogenous and exogenous mutational processes act over the evolutionary history of a malignant tumor, driven by abnormal DNA editing, mutagens or age-related DNA alterations, among others, to generat...
I F Tannock
I F Tannock
Access to essential anticancer medicines for children and adolescents in Europe [0.03%]
欧洲儿童和青少年抗癌基本药物的获取问题
G Vassal,O Kozhaeva,S Griskjane et al.
G Vassal et al.
Background: Essential anticancer medicines are an indispensable component of multidisciplinary treatment of paediatric malignancies. A European Society for Medical Oncology (ESMO) study reported inequalities in the availa...
Palbociclib in combination with endocrine therapy versus capecitabine in hormonal receptor-positive, human epidermal growth factor 2-negative, aromatase inhibitor-resistant metastatic breast cancer: a phase III randomised controlled trial-PEARL [0.03%]
帕博西尼与内分泌治疗联用对比卡培他滨治疗雌激素受体阳性、HER2阴性、非甾体类芳香化酶抑制剂耐药晚期乳腺癌的III期随机对照试验-Pearl研究
M Martin,C Zielinski,M Ruiz-Borrego et al.
M Martin et al.
Background: Palbociclib plus endocrine therapy (ET) is the standard treatment of hormone receptor-positive and human epidermal growth factor receptor 2-negative, metastatic breast cancer (MBC). However, its efficacy has n...
Relevance of body mass index as a predictor of systemic therapy outcomes in metastatic melanoma: analysis of the MelBase French cohort data☆ [0.03%]
体质指数作为预测转移性黑色素瘤全身治疗结果的指标的价值：来自法国MelBase队列数据的分析
Y Di Filippo,S Dalle,L Mortier et al.
Y Di Filippo et al.
Background: The 'obesity paradox' suggests that higher body mass index (BMI) is associated with better survival values in metastatic melanoma patients, especially those receiving targeted and immune checkpoint inhibitor t...
Longitudinal tracking of 97 esophageal adenocarcinomas using liquid biopsy sampling [0.03%]
利用液体活检对97例食管腺癌进行纵向追踪监测
E Ococks,A M Frankell,N Masque Soler et al.
E Ococks et al.
Background: The incidence of esophageal adenocarcinoma (EAC) is rapidly rising and has a 5-year survival rate of
Nasopharyngeal carcinoma: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up† [0.03%]
鼻咽癌：ESMO-EURACAN诊断、治疗和随访临床实践指南
P Bossi,A T Chan,L Licitra et al.
P Bossi et al.
Combination treatment of copanlisib and gemcitabine in relapsed/refractory PTCL (COSMOS): an open-label phase I/II trial [0.03%]
Copanlisib联合吉西他滨治疗复发/难治PTCL(COSMOS):一项开放性I/II期临床试验
H-Y Yhim,T Kim,S J Kim et al.
H-Y Yhim et al.
Background: Current treatment options for peripheral T-cell lymphomas (PTCLs) in the relapsed/refractory setting are limited and demonstrate modest response rates with rare achievement of complete response (CR). ...
F Lordick,M Nilsson,T Leong
F Lordick